F-1/A: Medicus Pharma Eyes Nasdaq Listing with $6.26 Million Unit Offering

Medicus Pharma Ltd. is seeking to raise capital and list on the Nasdaq through an offering of 1,200,000 units, each comprising a common share and a warrant.

Summary

• Medicus Pharma Ltd. is offering 1,200,000 units, each consisting of one common share and one warrant to purchase one common share.
• The warrants are immediately exercisable at a price equal to 100% of the unit price and expire five years from issuance.
• The company has applied to list its common shares and warrants on the Nasdaq Capital Market under the symbols 'MDCX' and 'MDCXW,' respectively.
• A 1-for-3 reverse stock split will be effective around the pricing date of the offering.
• The assumed initial public offering price is $5.22 per unit, based on the TSXV closing price on September 27, 2024, after giving effect to the Share Consolidation.
• Medicus Pharma has granted the underwriters a 45-day option to purchase up to 180,000 additional common shares and/or warrants to cover overallotments.
• The company intends to use the net proceeds to fund a Phase 2 proof of concept clinical trial for SkinJect for basal cell carcinoma treatment and for general corporate purposes.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of the company's technology and the significant risks associated with its development and commercialization. The sentiment is neutral, reflecting the inherent uncertainties in the biotech industry.

Positives

• The company has completed a Phase 1 study of SkinJect.
• SkinJect has the potential to treat a range of other common non-melanoma skin cancers as well as pre-cancerous lesions.

Negatives

• The company has a limited operating history and no history of earnings.
• As of June 30, 2024, the company had an accumulated deficit of approximately US$24.8 million.
• The Product is at an early stage of development, with uncertain market acceptance.
• There is no assurance that the U.S. Exchange will approve the listing of the common shares and the warrants.

Risks

• The company's financial results may vary significantly from forecasts.
• The progress, timing and completion of research, development and clinical trials are uncertain.
• The company's ability to market, commercialize, achieve market acceptance for and sell its products is uncertain.
• The company may require additional financing in the future, which may not be available on favorable terms or at all.
• The company operates in a highly competitive industry.
• The company relies on key personnel.
• The company's intellectual property is held under third-party licenses.
• The University of Pittsburgh may terminate the license agreement in certain circumstances.
• The company may infringe the intellectual property rights of others.
• The company may be unable to obtain marketing approval.
• The company may not be able to successfully execute its business strategy.

Future Outlook

The company expects R&D expenses to increase substantially as it advances product candidates through clinical trials and expands its pipeline.

Management Comments

• Our principal purpose is to advance the clinical development program of the Product, a novel, minimally invasive treatment for basal cell carcinoma and potentially other common forms of non-melanoma skin cancer.
• We also seek to opportunistically identify, evaluate and acquire accretive assets, properties or businesses.

Industry Context

The document provides an overview of the basal cell carcinoma market and current therapies, highlighting the limitations of existing treatments and the potential for SkinJect to offer a more robust alternative.

Comparison to Industry Standards

• The document mentions competitors with greater financial, technical, and marketing resources.
• It cites studies comparing the efficacy of imiquimod, 5-fluorouracil, and tazarotene to surgical treatments for basal cell carcinoma.
• The document references the University of Pittsburgh's research on microneedle arrays for delivering doxorubicin, providing a benchmark for the company's technology.

Related Party Transactions

• The company has an agreement with RBx, that provides for certain managerial positions to be filled from within RBx. Reimbursable salaries paid to RBx pursuant to this agreement are $125,000 per month.
• On May 3, 2024, certain directors and officers of the Company purchased $700,000 aggregate principal amount of 2025 Convertible Notes on the same terms as the investors who were not related to the Company.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• The success of the company's clinical trials and regulatory approvals will directly impact shareholder value.
• Employees' job security and compensation are tied to the company's financial performance.
• Customers (patients) could benefit from a new, minimally invasive treatment for basal cell carcinoma if SkinJect is successful.
• Suppliers and creditors are subject to the company's ability to secure funding and generate revenue.

Next Steps

• Fund Phase 2 proof of concept clinical trial for SkinJect.
• Potentially expand Phase 2 clinical trial to a pivotal trial.
• Potentially expand trials to cover other non-melanoma skin diseases.
• Seek regulatory approval for SkinJect.
• Pursue potential acquisitions of other clinical stage life sciences and biotechnology companies.

Key Dates

Keywords

Medicus Pharma, SkinJect, Units, Common Shares, Warrants, Nasdaq, Clinical Trial, Basal Cell Carcinoma, Doxorubicin, Microneedle Array, Offering, Biotech